Kenvue Inc. has announced a significant change in its ownership structure following its merger with Kimberly-Clark Corporation. This event is crucial as it not only alters Kenvue's operational framework but also has implications for the broader perfumes, cosmetics, and toilet preparations industry.
Kenvue Inc., classified under the SIC code 2844, specializes in perfumes, cosmetics, and other toilet preparations. The company trades on the New York Stock Exchange under the ticker KVUE. Recently, Kenvue has been active in filing various forms with the SEC, including multiple Form 4 submissions on November 4, 2026, indicating ongoing changes in ownership and management.
The recent SEC filing, accession number 0000950157-26-001198, details that Betsy D. Holden, a director at Kenvue, disposed of 37,794.81 Deferred Share Units (DSUs) on November 2, 2026. This transaction is part of the broader context of the merger with Kimberly-Clark, which was finalized on the same date. According to the filing, each share of Kenvue's common stock was exchanged for 0.14625 shares of Kimberly-Clark common stock, plus $3.50 in cash, as part of the merger consideration.
The filing also notes that the deferred share units were converted into Kimberly-Clark stock units, aligning with the terms of the merger agreement. This indicates a seamless transition for Kenvue's equity awards into the larger Kimberly-Clark framework.
This ownership change may have various implications for stakeholders, including employees, shareholders, and competitors within the industry. As Kenvue integrates into Kimberly-Clark, it may benefit from increased resources and market reach, which could alter competitive dynamics in the perfumes and cosmetics sector.
What happens next is not specified in the filing. However, the ongoing integration process and any further filings related to the merger are likely to provide additional insights into Kenvue's future direction under Kimberly-Clark's ownership.
Read Next
Rallybio Corp approves merger with Avenzo Therapeutics
FACT II Acquisition Corp. postpones extraordinary meeting
Wassil Jim Reports Stock Transactions for Vaxcyte, Inc.
Cowan Elvia Reports Stock Transactions in SEC Filing
Saiki Julie Reports New Stock Transactions at Azora Therapeutics
Davidson Acquires Over 524,000 Shares of Azora Therapeutics








